Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 204

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 204
---
 resale by the Selling Shareholder under the registration statement that includes this prospectus were issued and outstanding as of such date (without taking into account the 4.99% Ownership Limitation or the 19.99% Exchange Cap limitation), such shares would represent approximately 31.4% of the total number of our common shares outstanding as of February 10, 2025.

Although the SEPA provides that we may, in our discretion, from time to time after the date of the SEPA and during the term of the SEPA, direct the Selling Shareholder to purchase common shares from us in one or more Advances under the SEPA, for a maximum aggregate purchase price of up to $15,000,000, only 3,710,000 common shares (105,840 of which represent the Commitment Shares we issued to the Selling Shareholder pursuant to the SEPA as payment for the Selling Shareholder's commitment to purchase common shares under the SEPA) are being registered for resale under the registration statement that includes this prospectus. Assuming all of such 3,710,000 common shares were sold to the Selling Shareholder at the maximum 97.0% discount to the per share price of $2.75 (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding February 10, 2025; or (ii) the average Nasdaq Official Closing Price for the five Trading Days immediately preceding February 10, 2025), such number of shares would be insufficient to enable us to receive aggregate gross proceeds from the sale of such shares to the Selling Shareholder equal to the Selling Shareholder's $15,000,000 total aggregate purchase commitment under the SEPA. While the market price of our common shares may fluctuate from time to time after the date of this prospectus and, as a result, the actual purchase price to be paid by the Selling Shareholder under the SEPA for common shares, if any, may also fluctuate, in order for us to receive the full amount of the Selling Shareholder's commitment under the SEPA, it is possible that we may need to issue and sell more than the number of shares being registered for resale under the registration statement that includes this prospectus.

If it becomes necessary for us to issue and sell to the Selling Shareholder more shares than are being registered for resale under this prospectus in order to receive aggregate gross proceeds of $15,000,000 under the SEPA, we